血管闭合装置封堵子宫穿刺部位的可行性与潜在疗效:妊娠绵羊模型的初步结果
该研究在妊娠绵羊胎镜手术模型中评估Abbott Perclose血管闭合装置于子宫穿刺部位行经羊膜经子宫缝合的可行性与潜在疗效。10只妊娠绵羊共使用32枚装置,75%(24/32)成功放置,所有缝线在两次干预、剖宫产时及原位均见水密闭合。组织病理学证实装置入口周围机化性纤维化及Cx43过表达,作者认为该装置在临床前模型中可行且可能有效,并预期后续临床验证研究。
要点
- 妊娠绵羊胎镜模型中Perclose装置子宫穿刺部位缝合成功率为75%(24/32)。
- 所有成功放置的缝线在两次干预、剖宫产时及原位均达到水密闭合。
- 组织病理学见装置入口周围机化性纤维化及Connexin 43过表达。
核心结论
- 作者首次在胎镜手术临床前绵羊模型中采用多种正交方法证实,Perclose装置作为子宫穿刺口闭合的新方法可行且可能有效。
研究设计与样本
- 妊娠绵羊胎镜手术模型研究,2023年12月至2025年2月进行,纳入10只妊娠绵羊(其中4只为双胎妊娠),评估Abbott Perclose血管闭合装置在置入12-French外径套管前后缝合子宫入口处胞膜;可行性定义为两个独立手术团队在两个不同孕龄成功放置缝线;通过活体大体检查入口处水密闭合及产后组织病理学评估膜与子宫肌层愈合来显示潜在疗效;采用中线剖腹直接子宫入口、2 cm迷你剖腹及经皮三种腹部入路;组织病理学采用常规显微镜、三色染色及Connexin 43免疫组化;研究经机构动物护理与使用委员会批准(AN-2010)。
诊断标准与关键数值
- 可行性定义为两个独立手术团队在两个不同孕龄成功放置缝线;潜在疗效由活体大体检查入口处水密闭合以及产后组织病理学评估膜与子宫肌层机化性纤维化和愈合来判定;组织病理学见装置入口周围机化性纤维化及Connexin 43过表达。
临床应用与阅片要点
- 原文未据此给出临床推荐。
局限性
- 原文为临床前绵羊模型的初步结果;作者在结论中表示预期临床验证研究将提供转化数据及直接测量减少绒毛膜羊膜分离、早产前胎膜早破和早产疗效的手段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Membrane damage at or near the uterine entry site is a prevalent complication of fetal surgery and may result in chorioamniotic separation (CAS), preterm prelabor rupture of membranes (PPROM) and preterm birth. Transamniotic transuterine suturing approaches offer the potential to reduce the prevalence of CAS and PPROM accompanying fetoscopy, with the overarching aim of reducing preterm birth. This study aimed to explore the feasibility and potential efficacy of employing a novel vascular closure device for transamniotic transuterine suturing in a sheep model of fetoscopic surgery.
METHODS: This study employed a pregnant sheep model to simulate fetal surgery and was conducted between December 2023 and February 2025. We used multiple methodologies to evaluate the Abbott Perclose™ vascular closure device for suturing membranes at the uterine entry site before or after the insertion of a 12-French outer diameter cannula. Feasibility was defined as successful suture placement by two independent surgical teams at two different gestational ages. Potential efficacy was demonstrated by the watertight closure of the entry site during in-vivo gross examination, along with organizing fibrosis and healing of membranes and myometrium, as assessed by postdelivery histopathological evaluation. The procedures were conducted in two phases during the sheep's gestation. Three approaches were used for abdominal entry to access the uterus: midline laparotomy and direct uterine entry; 2-cm mini laparotomy allowing access to the uterus; and a percutaneous approach. Histopathological examination of samples from the entry sites was conducted using routine microscopy, trichrome staining and immunohistochemistry for Connexin 43 (Cx43). This study was approved by the Institutional Animal Care and Use Committee (AN-2010).
RESULTS: Ten pregnant sheep were included in this study, four of which had a twin pregnancy. The median gestational age at the occurrence of the first and second rounds of intervention was 85.5 and 104 days, respectively. Overall, 32 Perclose devices were used, and 75% (24/32) were placed successfully. Watertight closure of all sutures was observed during the first and second rounds of intervention, at Cesarean delivery and in situ. Histopathological examination confirmed organizing fibrosis surrounding the device entry site, in addition to overexpression of Cx43.
CONCLUSIONS: Employing multiple orthogonal approaches, we have shown for the first time that the Perclose device is both feasible and potentially efficacious as a novel means of uterine port closure in our preclinical sheep model of fetoscopic surgery. Inspired by our success in this preclinical model, we anticipate that clinical validation studies will provide translational data and a direct means of measuring efficacy in the reduction of CAS, PPROM and preterm birth. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Krispin E, Qaderi S, Javinani A, et al. Feasibility and efficacy of vascular closure device for sealing uterine entry site: preliminary results from pregnant sheep model. Ultrasound Obstet Gynecol. 2025. PMID: 40843471. doi:10.1002/uog.70012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。